Skip to Content

Join the 'HIV Infection' group to help and get support from people like you.

HIV Infection News

Related terms: Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome (AIDS), Acute HIV Infection, Acute Retroviral Syndrome, AIDS, AIDS-Related Complex, Chronic Symptomatic HIV Infection, HIV Infection, Acute, HIV Seroconversion Syndrome, Human Immunodeficiency Virus Infection, Primary HIV Infection, HIV, ARC, Acquired Immunodeficiency Syndrome, HIV/AIDS

FDA Approves Merck’s Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Appropriate Patients

Posted 16 days ago by Drugs.com

KENILWORTH, N.J.--(BUSINESS WIRE) August 30, 2018 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Delstrigo, a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg) for the treatment of HIV-1 infection in adult ...

FDA Approves Merck’s Pifeltro (doravirine) for the Treatment of HIV-1 in Appropriate Patients

Posted 1 Sep 2018 by Drugs.com

KENILWORTH, N.J.--(BUSINESS WIRE) August 30, 2018 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Pifeltro (doravirine, 100 mg), a new non-nucleoside reverse transcriptase inhibitor (NNRTI) to be administered in combination with other antiretroviral medicines. Pifeltro is indicated for the ...

Newer HIV Therapies Yield Big Gains But Racial Gaps Persist

Posted 21 Aug 2018 by Drugs.com

TUESDAY, Aug. 21, 2018 – Improved treatment has nearly tripled viral suppression rates among HIV patients in the United States over the past two decades, researchers report. But viral suppression rates remain lower among young people and black Americans, the researchers add. About 1.2 million U.S. adults have HIV, the virus that causes AIDS. Achieving and maintaining suppression of the virus is ...

New Drug of Last Resort, Ibalizumab, Tackles Resistant HIV

Posted 16 Aug 2018 by Drugs.com

THURSDAY, Aug. 16, 2018 – HIV, the virus that causes AIDS, is typically a manageable infection, but medications that keep the virus at bay don't work for everyone. Now, researchers have developed a new medication to help them. The U.S. Food and Drug Administration approved the drug – ibalizumab (Trogarzo) – in March. Phase 3 trial results were published in the Aug. 16 issue of the New England ...

HIV Doubles Heart Disease Risk

Posted 30 Jul 2018 by Drugs.com

MONDAY, July 30, 2018 – People with HIV are twice as likely to develop heart disease than those without the AIDS-causing virus, British researchers report. Their review of studies from 153 countries also found that HIV-associated heart disease has more than tripled in the past 20 years, as more people with HIV live longer. More than two-thirds of HIV-associated heart disease occurs in ...

FDA Approves Symtuza (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection

Posted 18 Jul 2018 by Drugs.com

TITUSVILLE, N.J, JULY 17, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved Symtuza (darunavir, cobicistat, emtricitabine and tenofovir alafenamide - D/C/F/TAF), the first and only complete, darunavir-based single-tablet regimen (STR) for the treatment of human immunodeficiency virus type 1 (HIV-1) in t ...

Antiviral Treatments Reduce Cancer Risk for HIV Patients

Posted 11 Jun 2018 by Drugs.com

MONDAY, June 11, 2018 – Long-term antiviral treatment cuts the risk of cancer in HIV patients as they age, a new study says. People with HIV are at increased risk for both AIDS-related cancers (Kaposi sarcoma, non-Hodgkin lymphoma or invasive cervical cancer) and non-AIDS-related cancers (lung and larynx cancer, melanoma and leukemia). Antiretroviral therapy (ART) is a major part of HIV ...

Human Trials Set for Experimental HIV Vaccine

Posted 6 Jun 2018 by Drugs.com

WEDNESDAY, June 6, 2018 – An experimental HIV vaccine protected animals from dozens of strains of HIV. And a human trial of the vaccine is expected to begin in the second half of 2019, according to U.S. researchers. The vaccine targets a vulnerable site on HIV – the virus that causes AIDS – and triggered antibody production in mice, guinea pigs and monkeys, according to researchers with the ...

FDA Medwatch Alert: Juluca, Tivicay, Triumeq (dolutegravir): FDA to Evaluate - Potential Risk of Neural Tube Birth Defects

Posted 20 May 2018 by Drugs.com

ISSUE: Serious cases of neural tube birth defects involving the brain, spine, and spinal cord have been reported in babies born to women treated with dolutegravir used to treat human immunodeficiency virus (HIV). Preliminary results from an ongoing observational study in Botswana found that women who received dolutegravir at the time of becoming pregnant or early in the first trimester appear to ...

AHA: The Link Between HIV and High Blood Pressure

Posted 18 May 2018 by Drugs.com

FRIDAY, May 18, 2018 (American Heart Association) – People with HIV are more likely than people without the virus to have high blood pressure, in part because of treatments and repercussions of the condition itself, a new review of research shows. Learning more about the underlying mechanisms of high blood pressure in people with HIV is critical in preventing one of the leading conditions that ...

FDA Approves Expanded Indication for Truvada (emtricitabine and tenofovir disoproxil fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents

Posted 16 May 2018 by Drugs.com

FOSTER CITY, Calif.--(BUSINESS WIRE)--May 15, 2018-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)—in combination with safer sex practices—to reduce the risk of sexually acquired HIV-1 in at-risk adolescents. The safety and efficacy profile of Tru ...

HIV Drug, Tenofovir, Appears Safe During Pregnancy

Posted 26 Apr 2018 by Drugs.com

WEDNESDAY, April 25, 2018 – Drugs to prevent HIV-positive pregnant women from infecting their unborn babies appear safe and don't raise the risk for premature birth or infant death, new research indicates. The U.S. scientists said their findings should ease worries among expectant mothers treated with antiviral regimens that contain the drug tenofovir disoproxil fumarate (TDF). "The analysis ...

Mylan Introduces Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) Triple Combo Once-Daily HIV Treatment in the U.S.

Posted 8 Apr 2018 by Drugs.com

HERTFORDSHIRE, England and PITTSBURGH, March 28, 2018 /PRNewswire/ – Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will introduce in the U.S. a third cost-saving HIV combination. The U.S. Food and Drug Administration (FDA) approved Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) 600 mg/300 mg/300 mg tablets, a once-daily, single-tablet regimen ...

Mylan Introduces Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) Triple Combo Once-Daily HIV Treatment in the U.S.

Posted 8 Apr 2018 by Drugs.com

HERTFORDSHIRE, England and PITTSBURGH, March 28, 2018 /PRNewswire/ – Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will introduce in the U.S. a third cost-saving HIV combination. The U.S. Food and Drug Administration (FDA) approved Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) 600 mg/300 mg/300 mg tablets, a once-daily, single-tablet regimen ...

U.S. Deaths From Infectious Diseases Decline, But Not Everywhere

Posted 27 Mar 2018 by Drugs.com

TUESDAY, March 27, 2018 – Though fewer Americans are now dying from infectious diseases, great disparities persist across the country, a new study finds. Between 1980 and 2014, just over 4 million Americans died from infectious diseases. But while overall infectious disease deaths have dropped almost 19 percent, death rates differed widely by county. A number of factors fuel these disparities, ...

Page 1 2 3 ... Next

Ask a Question

Further Information

Related Condition Support Groups

Pre-Exposure Prophylaxis, Viral Infection

Related Drug Support Groups

Atripla, Truvada, Stribild, Triumeq, Genvoya, Complera, Viread, Prezista, lamivudine, view more... tenofovir, Norvir, efavirenz, Descovy, Odefsey, Trogarzo, immune globulin intravenous, Epzicom, ritonavir, Kaletra, dolutegravir, abacavir, Reyataz, Biktarvy, Tivicay, Symfi, Cimduo, emtricitabine, Symfi Lo, Sustiva, Symtuza, Epivir, Edurant, Retrovir, Trizivir, Prezcobix, Carimune, Octagam, Isentress, Intelence, Juluca, Lexiva, cobicistat, nevirapine, zidovudine, amprenavir, abacavir / dolutegravir / lamivudine, darunavir, stavudine, lamivudine / zidovudine, emtricitabine / tenofovir, atazanavir / cobicistat, Carimune NF, Telzir, Zerit XR, tipranavir, Iveegam En, zalcitabine, saquinavir, Panglobulin, Gamimune N 10%, Gamimune N 5%, Polygam S / D, Gammar-P IV, Venoglobulin-S 10%, Venoglobulin-S 5%, Sandoglobulin, Gamimune, nelfinavir, Gammaplex, fosamprenavir, Pifeltro, abacavir / lamivudine / zidovudine, atazanavir, delavirdine, didanosine, efavirenz / emtricitabine / tenofovir, enfuvirtide, Dutrebis, Gammar IV, indinavir, Evotaz, Tybost, Vitekta, lopinavir / ritonavir, maraviroc, Viramune XR, Gammagard S / D, raltegravir, Selzentry, cobicistat / darunavir / emtricitabine / tenofovir alafenamide, Videx, Rescriptor, elvitegravir, Agenerase, Ziagen, doravirine / lamivudine / tenofovir, doravirine, lamivudine / nevirapine / zidovudine, ibalizumab, Emtriva, lamivudine / tenofovir, efavirenz / lamivudine / tenofovir, bictegravir / emtricitabine / tenofovir alafenamide, dolutegravir / rilpivirine, emtricitabine / tenofovir alafenamide, emtricitabine / rilpivirine / tenofovir alafenamide, cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide, lamivudine / raltegravir, Videx EC, Fuzeon, cobicistat / darunavir, Zerit, calanolide a, Panglobulin NF, Flebogamma, etravirine, emtricitabine / lopinavir / ritonavir / tenofovir, Hivid, Aptivus, emtricitabine / nelfinavir / tenofovir, Invirase, abacavir / lamivudine, Fortovase, rilpivirine, Viramune, Viracept, emtricitabine / rilpivirine / tenofovir, Combivir, cobicistat / elvitegravir / emtricitabine / tenofovir, Epivir-HBV, Crixivan, Delstrigo